Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia.
Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis.
Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.
Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod.
Neuroprotection in Huntington's disease: a 2-year study on minocycline.
Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin.
The recurrent Guillain-Barré syndrome: a long-term population-based study.
Rhythmic auditory cueing to improve walking in patients with neurological conditions other than Parkinson's disease - what is the evidence?
Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way.
A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1).
Minocycline effects on the CSF proteome of Experimental Autoimmune Encephalomyelitis rats.
Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
Modifiable Comorbidities and Disability in Multiple Sclerosis.
Shape Analysis of the Corpus Callosum and Cerebellum in Female MS Patients with Different Clinical Phenotypes.
Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis.
Lack of response to rituximab therapy in patients with neuromyelitis optica: Response to Kim and Kim.
Small Molecules in Stem Cell Research.
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.
The therapeutic value of yoga in neurological disorders.
Neurotrophic factors and their effects in the treatment of multiple sclerosis.
Use of Complementary and Alternative Medicine among People with Multiple Sclerosis in the Nordic Countries.

Pages